Mein Warenkorb

Integrin alpha V beta 8

Integrin alpha V beta 8 Molekülinformation

Englischer Nameintegrin alpha V/beta 8Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3Target-Aliasalphavbeta8 integrin
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer Nameintegrin alpha V/beta 8
Target-Aliasalphavbeta8 integrin
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

Integrin alpha V beta 8 Molekülhintergrund

Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Integrin alpha V beta 8 Molekülalias

Integrin alpha V beta 8,ITGAV&ITGB8

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
NesvategrastSF-0166; OTT-166(OcuTerra Therapeutics)Phase 2 ClinicalOcuTerra Therapeutics Inc, Scifluor Life Sciences IncDiabetic macular oedema; Diabetic Retinopathy; Macular Degeneration
Details
CRB-601CRB-601Phase 2 ClinicalCorbus Pharmaceuticals Holdings Inc, Uc San FranciscoSolid tumours
Details
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics IncSolid tumours
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns